Humoral immune response after different SARS-CoV-2 vaccination regimens

Table 1 Individuals included in this study

Study groups	Number of individuals after 1st/2nd vaccination	Median age in years	Age or age span in years	Gender (female/male)	Time (median) from 1st vaccination up to 1st serum sampling in days	Time (median) from 2nd vaccination up to 2nd serum sampling in days
Heterologous vaccination scheme
AZD1222/BNT162b2	28/40	27	18–56	32/8	69	15
AZD1222/BNT162b2 (subgroup)†	-/9	43	23–56	7/2	Not applicable	14
AZD1222/mRNA-1273	2/2	‡	24, 45	2/0	64, 69 (‡)	10, 14 (‡)
Homologous vaccination scheme
AZD1222	8/9	41	23–61	6/3	69	16
BNT162b2	8/8	35	23–51	7/1	34	14

†After the 2nd vaccination, several sera were also tested for the presence of virus-neutralising antibodies against the SARS-CoV-2 delta variant of concern (B.1.617.2). For this purpose, individuals from the group of heterologous vaccinations whose age and gender largely corresponded to those with homologous vaccinations were chosen. This subgroup is separately presented. ‡Calculating the median does not make sense if there are two values

ISSN: 1741-7015